Loading
A phase 1 trial of Lunresertib run by University Health Network, Toronto, active and no longer recruiting.
Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer is a phase 1 interventional study registered as NCT06107868 by University Health Network, Toronto, with 6 participants planned, started 2024-03-20. Conditions recorded: Recurrent Ovarian Cancer, Recurrent Uterine Cancer, Metastatic Cancer and Advanced Cancer. Interventions recorded: RP-6306, Carboplatin and Paclitaxel.
Shares Lunresertib, Repare Therapeutics, Debiopharm, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Lunresertib, Repare Therapeutics, Debiopharm, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Lunresertib, Repare Therapeutics, Debiopharm, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Lunresertib, Repare Therapeutics, Debiopharm, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Lunresertib, Repare Therapeutics, Debiopharm and the tag pipeline.
Shares Repare Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Repare Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Debiopharm and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/